Veliky Novgorod

Researchers are evaluating the safety and effectiveness of a new bevacizumab drug made by Mabscale, LLC, compared to Avastin, both combined with paclitaxel and carboplatin, for treating adults with advanced or inoperable non-squamous non-small cell lung cancer NSCLC. This phase III trial aims to show that the new bevacizumab works as well and is as safe as Avastin. The study also looks at how the drug is processed in the body. Participants are randomly assigned to one of two groups. One group receives the Mabscale bevacizumab with paclitaxel and carboplatin, and the other gets Avastin with the same chemotherapy drugs. Treatment cycles last about three weeks, with up to six cycles initially. After that, eligible patients continue with bevacizumab alone every three weeks. The study is double-blind, so neither patients nor researchers know who receives which bevacizumab. During the study, patients will undergo regular assessments including tumor measurements and blood tests. Researchers measure the tumor response at 18 weeks and track progression-free and overall survival at 18 and 42 weeks. The duration of response is also evaluated up to 48 weeks. Safety and side effects are closely monitored throughout the trial, which started in 2023 and will continue until 2027. Participants are followed closely to assess the treatments impact and safety.

Researchers are evaluating the drug 4-MUST to understand its effectiveness, safety, and tolerability in treating patients with chronic cholecystitis and biliary dyskinesia. This study compares different doses of 4-MUST with a placebo to see how well the drug reduces upper abdominal pain and gastrointestinal symptoms. The trial is a phase 2, prospective, randomized, double-blind, placebo-controlled study designed to provide detailed insight into the drugs impact on these digestive conditions. Participants will be randomly assigned to one of four groups. One group receives 1 tablet of 4-MUST 128 mg plus 2 placebo tablets three times daily, another receives 2 tablets of 4-MUST 256 mg plus 1 placebo tablet three times daily, a third group takes 3 tablets of 4-MUST 384 mg three times daily, and the last group receives 3 placebo tablets three times daily. The treatment lasts for 29 days, with doses given three times a day, followed by assessment and monitoring. During the study, participants will undergo regular evaluations including pain measurement using a Visual Analog Scale VAS, gastrointestinal symptom rating via questionnaires, and quality of life assessments with the SF-36 questionnaire. Safety will be monitored through adverse event tracking, physical examinations, vital signs, laboratory tests, and electrocardiograms at multiple time points throughout the 29-day period and up to day 36. These thorough assessments aim to capture the drugs effects and tolerability over the course of treatment.

This research aims to evaluate the effectiveness and safety of different doses of the drug Grammidin with anesthetic, delivered as a metered dose topical spray, for treating acute infectious and inflammatory diseases of the pharynx. These conditions include acute pharyngitis, nasopharyngitis, and exacerbation of chronic pharyngitis. The study compares Grammidin spray with Septolete Total lozenges as an active comparator in a Phase 2 randomized trial. Participants are assigned to one of three groups one group receives Grammidin spray with 2 sprays every 6 hours three times daily for 7 days, another group receives Grammidin spray with 4 sprays on the same schedule, and the third group takes Septolete Total lozenges 1 lozenge every 6 hours, up to 3 lozenges daily for 7 days. Treatments are taken under fed conditions. The study is open-label, multicenter, and parallel-group. During the 8-day study period, participants attend visits on Day 1, Day 5, and Day 8 for assessments including sore throat severity measured by Visual Analog Scale VAS and the Clinical Symptom Severity Scale. Researchers monitor clinical symptoms, inflammation signs, and intoxication syndrome. Safety is evaluated through recording adverse events, vital signs, physical examinations, and multiple laboratory tests such as blood counts, blood chemistry, and urinalysis. The study tracks treatment adherence and overall patient outcomes over the three visits.